Pilot study of 5-azacytidine (5-AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia

✍ Scribed by Kritz, Alan D.; Raptis, George; Menendez-Botet, Celia; Maslak, Peter; Jakubowski, Ann

• Publisher: John Wiley and Sons
• Year: 1996
• Tongue: English
• Weight: 481 KB
• Volume: 51
• Category: Article
• ISSN: 0361-8609
• DOI: 10.1002/(sici)1096-8652(199602)51:2<117::aid-ajh4>3.0.co;2-0

✦ Synopsis

5-azacytidine (5-AZA) and carboplatin (CBDCA) are two agents which have demonstrated antileukemic activity In a number of phase 1-11 trials. Their mechanisms of action and pharmacology related to cell resistance suggested sultabiiity for combination therapy. The aim of this pilot study was to evaluate the effects of this combination in the treatment of patients with reiapsedhefractory acute leukemia. A total o f 21 patients was enrolled. 5-azacytidine, at doses ranging from 50-150 mglm2/day, was administered as a 2-hr infusion for 5 consecutive days. On day 3, patients began a 5-day course of CBDCA given as a 24-hr continuous intravenous infusion of 250 mglm2/day. There were no complete remissions with this regimen. Although there were three partial responses, these were generally of short duration. Nonhematoioglc toxicities were mild. No correiatlon was seen between response and serum platinum levels. These results demonstrate that the 5 -A W CBDCA combination is ineffective therapy for heavily pretreated patients with acute leukemia. o 1996 w t l e y -~i ~~, Ine.